Drugs / sisunatovir
sisunatovir
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06102174 | Feb → Sep 2024 | respiratory syncytial virus infectious disease | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05987072 | Nov → Dec 2023 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06105983 | Nov 2023 → Jul 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06037031 | Oct 2023 → Jul 2024 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05994963 | Sep 2023 → Feb 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05857644 | Jun 2023 → Feb 2024 | liver disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05878522 | May → Oct 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05712460 | Feb → Apr 2023 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05873764 | May → Jul 2022 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04065698 | Aug → Sep 2019 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03782662 | Nov 2018 → Mar 2019 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04267822 | Jun 2020 → Jun 2023 | disease related to hematopoietic stem cell transplant, respiratory syncytial virus infectious disease | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT04225897 | Nov 2019 → Dec 2022 | respiratory syncytial virus infectious disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT03258502 | Jul → Oct 2017 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06079320 | Dec 2023 → Sep 2024 | respiratory syncytial virus infectious disease | Pfizer | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sisunatovir | “The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (called sisunatovir/RV521) for the potential treatment of...” NCT03258502 ↗8“Sisunatovir is an investigational respiratory syncytial virus (RSV) antiviral that was effective in an adult human viral challenge study.” PMID 41673909 ↗ Feb 2026 “study medicine (sisunatovir)” NCT05873764 ↗ |
| Known as | PF-07923568 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06037031 ↗ |
| Known as | RV-521 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297497 ↗ |
| Known as | RV521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04065698 ↗ |
| Known as | RV521.HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297497 ↗ |
| Known as | SISUNATOVIR HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297497 ↗ |
| Action | Inhibit | “RV521, a small-molecule antiviral inhibitor of the RSV-F protein” PMID 31712214 ↗ Jan 2020 |
| Modality | Small molecule | “RV521, a small-molecule antiviral inhibitor of the RSV-F protein” PMID 31712214 ↗ Jan 2020 |
| Route | Oral | “RV521 drug substance in capsule for oral administration” NCT03258502 ↗ |